INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 180 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is 1.51 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $59,000 | – | 4,215 | +30007.1% | 0.00% | – |
| Q1 2022 | $0 | -100.0% | 14 | -99.1% | 0.00% | -100.0% |
| Q3 2021 | $22,000 | -73.8% | 1,513 | -55.2% | 0.00% | -75.0% |
| Q4 2020 | $84,000 | +833.3% | 3,381 | +1533.3% | 0.00% | +300.0% |
| Q3 2020 | $9,000 | 0.0% | 207 | +44.8% | 0.00% | -66.7% |
| Q3 2019 | $9,000 | -66.7% | 143 | -67.5% | 0.00% | -78.6% |
| Q1 2018 | $27,000 | +50.0% | 440 | +44.7% | 0.01% | 0.0% |
| Q4 2017 | $18,000 | -5.3% | 304 | -8.4% | 0.01% | +7.7% |
| Q3 2017 | $19,000 | 0.0% | 332 | +111.5% | 0.01% | -35.0% |
| Q2 2017 | $19,000 | -13.6% | 157 | -20.7% | 0.02% | -31.0% |
| Q1 2017 | $22,000 | +340.0% | 198 | +371.4% | 0.03% | +480.0% |
| Q4 2016 | $5,000 | +400.0% | 42 | +500.0% | 0.01% | +150.0% |
| Q1 2016 | $1,000 | -96.7% | 7 | -93.5% | 0.00% | -92.3% |
| Q1 2015 | $30,000 | – | 107 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chicago Capital Management, LLC | 185,781 | $4,611,565 | 12.16% |
| Samsara BioCapital, LLC | 640,688 | $11,878,356 | 3.64% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,203,295 | $40,849,089 | 2.14% |
| Versor Investments LP | 378,480 | $7,017,019 | 1.42% |
| Magnetar Financial LLC | 2,407,209 | $44,629,655 | 1.14% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,077,893 | $38,524,136 | 0.85% |
| Fort Baker Capital Management LP | 430,600 | $7,983,324 | 0.74% |
| EHP Funds Inc. | 84,210 | $1,561,253 | 0.73% |
| Terrapin Asset Management, LLC | 30,000 | $556,200 | 0.63% |
| AQR Arbitrage LLC | 734,970 | $13,626,344 | 0.61% |